您当前的位置: 首页 > 资源详情

MedicalXpres,10月4日,Study: For unvaccinated, reinfection by SARS-CoV-2 is likely

编译者:YUTING发布时间:Oct 13, 2021点击量:36 来源栏目:最新研究

Throughout the COVID-19 pandemic, there has been much uncertainty about how long immunity lasts after an unvaccinated person is infected with SARS-CoV-2.

Now a team of scientists led by faculty at Yale School of Public Health and the University of North Carolina at Charlotte have an answer: Strong protection following natural infection is short-lived.

"Reinfection can reasonably happen in three months or less," said Jeffrey Townsend, the Elihu Professor of Biostatistics at the Yale School of Public Health and the study's lead author. "Therefore, those who have been naturally infected should get vaccinated. Previous infection alone can offer very little long-term protection against subsequent infections."

The study, published in the journal The Lancet Microbe, is the first to determine the likelihood of reinfection following natural infection and without vaccination.

Townsend and his team analyzed known reinfection and immunological data from the close viral relatives of SARS-CoV-2 that cause "common colds," along with immunological data from SARS-CoV-1 and Middle East Respiratory Syndrome. Leveraging evolutionary principles, the team was able to model the risk of COVID-19 reinfection over time.

Reinfections can, and have, happened even shortly after recovery, the researchers said. And they will become increasingly common as immunity wanes and new SARS-CoV-2 variants arise.

"We tend to think about immunity as being immune or not immune. Our study cautions that we instead should be more focused on the risk of reinfection through time," said Alex Dornburg, assistant professor of bioinformatics and genomics at the University of North Carolina at Charlotte, who co-led the study. "As new variants arise, previous immune responses become less effective at combating the virus. Those who were naturally infected early in the pandemic are increasingly likely to become reinfected in the near future."

The team's data-driven model reveals striking similarities to the reinfection risks over time between SARS-CoV-2 and endemic coronaviruses.

"Just like common colds, from one year to the next you may get reinfected with the same virus," Townsend said. "The difference is that, during its emergence in this pandemic, COVID-19 has proven to be much more deadly."

A hallmark of the modern world is going to be the evolution of new threats to human health, Townsend added. Evolutionary biology—which provided the theoretical foundations for these analyses—is traditionally considered a historical discipline.

"However, our findings underscore its important role in informing decision-making, and provide a crucial steppingstone toward robust knowledge of our prospects of resistance to SARS-CoV-2 reinfection," he said.

提供服务:导出本资源
  1. 1 Nature,11月10日,Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility
  2. 2 11月10日_研究人员分析宿主基因对COVID-19严重程度和易感性的影响
  3. 3 11月11日_新冠药物Remestemcel-L二期临床的中期分析结果积极
  4. 4 11月11日_CDC呼吁制定通用口罩规定以减少新冠传播
  5. 5 SSRN,2月20日,Dynamics of the Latest 2019 Novel Coronavirus Disease Epidemic in China: A Descriptive Study
  6. 6 SSRN,2月20日,Mental Health Problems and Social Media Exposure During COVID-19 Outbreak
  7. 7 SSRN,2月20日,Evaluating Incidence and Impact Estimates of the Coronavirus Outbreak from Official and Non-Official Chinese Data Sources
  8. 8 SSRN,2月20日,Clinical Characteristics and Treatment of Patients Infected with COVID-19 in Shishou, China
  9. 9 Nature,11月10日,Mobility network models of COVID-19 explain inequities and inform reopening
  10. 10 1月27日_Nature报道中国新型冠状病毒最新研究进展:病毒传播速度有多快?
  1. 1 11月22日_感染无害冠状病毒可增强针对SARS-CoV-2的免疫力
  2. 2 Medicalxpress,11月22日,Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape
  3. 3 11月22日_科学家开发出一种可同时测量针对SARS-CoV-2的 T细胞和抗体反应的方法
  4. 4 Medicalxpress,11月22日,Pfizer says COVID shot 100% effective in adolescents after 4 months
  5. 5 11月18日_传播性增强和/或部分免疫逃逸的SARS-CoV-2变体对人群的影响
  6. 6 11月22日_辉瑞的COVID-19疫苗在接种4个月后对青少年的有效率为100%
  7. 7 Medicalxpress,11月18日,Simple, synthetic structure that mimics surface of SARS-CoV-2 mounts robust immune response in mice
  8. 8 11月18日_模拟SARS-CoV-2表面的简单合成结构在小鼠体内引发强大的免疫反应
  9. 9 11月17日_Zosano宣布在其微针贴片系统上成功配制COVID-19候选疫苗
  10. 10 11月18日_新分析预测疫苗针对SARS-CoV-2的保护作用

版权所有@2017中国科学院文献情报中心

制作维护:中国科学院文献情报中心信息系统部地址:北京中关村北四环西路33号邮政编号:100190